Bio-Rad wins motion against rival 10X Genomics in district court
Category: #healthcare  By Mateen Dalal  Date: 2019-07-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bio-Rad wins motion against rival 10X Genomics in district court

The court has allowed 10X Genomics to sell products for use with already sold systems, subject to royalty payment.

Bio-Rad Laboratories Inc., a manufacturer of clinical diagnostic products and life science research, has recently announced that the Delaware District Court has approved its motion for permanent injunction of biotechnology firm 10X Genomics from conducting any sales of infringing products to new customers and fulfilling its request for damages and pre- and post-judgement interest.

Reportedly, the court has also approved Bio-Rad’s agreement to allow 10X to sell products for use with prior sold systems, subject to royalty payment.

Reliable reports cite that the court’s decision follows its earlier verdict affirming the collective finding of a jury that 10X Genomics intentionally infringed three U.S. patents possessed by the University of Chicago and licensed to Bio-Rad Laboratories, Inc. As per the jury’s findings last year, all the patents were valid and infringed, 10X’s infringement was intentional and the claimants were entitled to a compensation of $23.9 million for damages.

Reportedly, 10X Genomics almost had the jury’s verdict reversed, but on July 2019, the judge denied the company’s motions and issued its decision in favor of the jury.

Speaking on the move, Norman Schwartz, President & CEO, Bio-Rad, said that the company is pleased with the court’s decisions. He claims that the decision successfully maintains the jury’s grant of damages and defends the company’s patent rights by offering an injunction.

For the uninitiated, Bio-Rad Laboratories is a world leader in manufacturing, developing and marketing a broad range of ground-breaking products for clinical diagnostic market and life science research. The company’s products aim at improving healthcare and advance medical discovery process.

 Bio-Rad is also known for conducting business with hospitals, university and research institutions, biotechnology, commercial laboratories, public health and pharmaceutical firms. Notably, the company has an international network of operations with over 8,000 employees worldwide. In addition, it has recorded revenue of over $2.2 billion in 2018.  

Source Credit : https://www.businesswire.com/news/home/20190724005938/en/Delaware-District-Court-Grants-Bio-Rad%E2%80%99s-Motion-Permanent

https://www.law.com/therecorder/2019/07/24/bio-rad-wins-order-excluding-competitors-gene-sequencing-technology-products/?slreturn=20190625064659

 

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...

Disney stock soars as Disney+ reaches 10 million sign ups on day 1
Disney stock soars as Disney+ reaches 10 million sign ups on day 1
By Mateen Dalal

Reports confirm that Walt Disney Co shares climbed to a record high after the entertainment company ...

China’s Xpeng Motors secures $400m to expand electric car production
China’s Xpeng Motors secures $400m to expand electric car production
By Mateen Dalal

  Xpeng has already launched vehicles like G3 SUV and P7 sedan Xpeng and investors like Xia...